Active Ingredient History
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is sold under the brand name Camptosar among others. CAMPTOSAR is a topoisomerase inhibitor indicated for: • First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. • Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Colorectal Neoplasms (approved 1996)
Adenocarcinoma (Phase 3)
Adenocarcinoma, Mucinous (Phase 1)
Adenoma, Islet Cell (Phase 2)
Angiogenesis Modulating Agents (Phase 2)
Antibody-Dependent Cell Cytotoxicity (Phase 2)
Antineoplastic Agents (Phase 3)
Anus Neoplasms (Phase 1)
Appendiceal Neoplasms (Phase 1)
Appendix (Phase 1)
Ascorbic Acid (Phase 3)
Astrocytoma (Phase 2)
Bile Duct Neoplasms (Phase 2/Phase 3)
Biliary Tract Neoplasms (Phase 2)
Bone Neoplasms (Phase 2)
Brain Diseases (Phase 1)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 3)
Burkitt Lymphoma (Phase 1)
Carcinoma (Phase 3)
Carcinoma, Adenoid Cystic (Phase 1)
Carcinoma, Basal Cell (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Mucoepidermoid (Phase 1)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Ovarian Epithelial (Phase 1)
Carcinoma, Pancreatic Ductal (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 3)
Carcinoma, Verrucous (Phase 2)
Central Nervous System Neoplasms (Phase 2)
Cholangiocarcinoma (Phase 3)
Chondrosarcoma (Phase 1)
Choroid Plexus Neoplasms (Phase 3)
Cognition Disorders (Phase 2)
Colonic Neoplasms (Phase 4)
Colorectal Neoplasms (Phase 4)
Craniopharyngioma (Phase 2)
Cytoreduction Surgical Procedures (Phase 2)
Dermatology (Phase 2)
Desmoplastic Small Round Cell Tumor (Phase 1/Phase 2)
Diarrhea (Phase 3)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Digestive System Diseases (Phase 1/Phase 2)
Digestive System Neoplasms (Phase 3)
Disease Progression (Phase 2)
DNA Mismatch Repair (Phase 2)
Docetaxel (Phase 2/Phase 3)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 3)
Drug Therapy, Combination (Phase 2)
Duodenal Neoplasms (Phase 1)
Endocrine Gland Neoplasms (Phase 1/Phase 2)
Endocrine System Diseases (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 2)
Ependymoma (Phase 2)
ErbB Receptors (Phase 2)
Esophageal Neoplasms (Phase 4)
Esophageal Squamous Cell Carcinoma (Phase 2)
Exanthema (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fluorouracil (Phase 2/Phase 3)
Gallbladder Neoplasms (Phase 2)
Ganglioglioma (Phase 1)
Ganglioneuroblastoma (Phase 2)
Ganglioneuroma (Phase 1)
Gastrointestinal Neoplasms (Phase 3)
Gastrointestinal Stromal Tumors (Phase 1)
General Surgery (Phase 3)
Genes, erbB-2 (Phase 2)
Glioblastoma (Phase 2/Phase 3)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Graft vs Host Disease (Phase 2)
Granuloma (Phase 1)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hemangiosarcoma (Phase 2)
Hepatoblastoma (Phase 3)
Hodgkin Disease (Phase 1)
Intestinal Neoplasms (Phase 4)
Intraocular Lymphoma (Phase 1)
Irinotecan (Phase 2/Phase 3)
Kidney Diseases (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Liver Diseases (Phase 2)
Liver Neoplasms (Phase 3)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 2)
Lymphoma, AIDS-Related (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphomatoid Granulomatosis (Phase 1)
Medulloblastoma (Phase 2)
Melanoma (Phase 1)
Meningioma (Phase 2)
Mesothelioma (Phase 1)
Mesothelioma, Malignant (Phase 1/Phase 2)
Microsatellite Instability (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Mutation (Phase 3)
Nasopharyngeal Carcinoma (Phase 1)
Nasopharyngeal Neoplasms (Phase 1)
Nausea (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasm Recurrence, Local (Phase 3)
Neoplasms ()
Neoplasms, Bone Tissue (Phase 3)
Neoplasms by Histologic Type (Phase 3)
Neoplasms, Connective and Soft Tissue (Phase 3)
Neoplasms, Connective Tissue (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Glandular and Epithelial (Phase 1/Phase 2)
Neoplasms, Second Primary (Phase 2)
Neoplasms, Unknown Primary (Phase 3)
Neoplastic Syndromes, Hereditary (Phase 2)
Neuroblastoma (Phase 3)
Neuroectodermal Tumors (Phase 2)
Neuroendocrine Tumors (Phase 3)
Neutropenia (Phase 1)
Oligodendroglioma (Phase 2)
Optic Nerve Glioma (Phase 1/Phase 2)
Oropharyngeal Neoplasms (Phase 1)
Osteosarcoma (Phase 2)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 2)
Oxaliplatin (Phase 2/Phase 3)
Pancreatic Diseases (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 3)
Papilloma, Inverted (Phase 1)
Penile Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 3)
Pinealoma (Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Proto-Oncogene Proteins B-raf (Phase 2)
Pseudomyxoma Peritonei (Phase 1)
Radiation (Phase 2)
Rare Diseases (Phase 3)
ras Proteins (Phase 2)
Rectal Neoplasms (Phase 3)
Rhabdoid Tumor (Phase 2)
Rhabdomyosarcoma (Phase 3)
Rhabdomyosarcoma, Alveolar (Phase 3)
Rhabdomyosarcoma, Embryonal (Phase 3)
Salivary Gland Neoplasms (Phase 1)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 3)
Sepsis (Phase 2)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 4)
Spinal Cord Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 4)
Thrombocytopenia (Phase 2)
Tongue Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 1)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Uterine Diseases (Phase 2)
Wilms Tumor (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
